Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

L. Wieske; E.W. Stalman; P.J.K. van Dam; L.Y. Kummer; M. Steenhuis; Z.L.E. van Kempen; J. Killestein; A.G. Volkers; S.W. Tas; L. Boekel; G. Wolbink; A. van der Kooi; J. Raaphorst; M. Lowenberg; B. Takkenberg; G.R.A.M. D'Haens; P.I. Spuls; M.W. Bekkenk; A.H. Musters; N.F. Post; A.L. Bosma; M.L. Hilhorst; Y. Vegting; F.J. Bemelman; A. Voskuyl; B. Broens; A.P. Sanchez; C.A.C.M. van Els; J. De Wit; A. Rutgers; K. de Leeuw; B. Horvath; J.J.G.M. Verschuuren; A.M. Ruiter; L. van Ouwerkerk; D. van der Woude; C.F. Allaart; Y.K.O. Teng; P. van Paassen; M.H. Busch; P.B.P. Jallah; E. Brusse; P.A. van Doorn; A.E. Baars; D. Hijnen; C.R.G. Schreurs; W.L. Van der Pol; H.S. Goedee; S. Keijzer; J. Keijser; T2B! immunity against SARS-CoV-2 study group

doi:10.1136/ard-2022-223464

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

L. Wieske, E.W. Stalman^*, P.J.K. van Dam, L.Y. Kummer, M. Steenhuis, Z.L.E. van Kempen, J. Killestein, A.G. Volkers, S.W. Tas, L. Boekel, G. Wolbink, A. van der Kooi, J. Raaphorst, M. Lowenberg, B. Takkenberg, G.R.A.M. D'Haens, P.I. Spuls, M.W. Bekkenk, A.H. Musters, N.F. PostA.L. Bosma, M.L. Hilhorst, Y. Vegting, F.J. Bemelman, A. Voskuyl, B. Broens, A.P. Sanchez, C.A.C.M. van Els, J. De Wit, A. Rutgers, K. de Leeuw, B. Horvath, J.J.G.M. Verschuuren, A.M. Ruiter, L. van Ouwerkerk, D. van der Woude, C.F. Allaart, Y.K.O. Teng, P. van Paassen, M.H. Busch, P.B.P. Jallah, E. Brusse, P.A. van Doorn, A.E. Baars, D. Hijnen, C.R.G. Schreurs, W.L. Van der Pol, H.S. Goedee, S. Keijzer, J. Keijser, T2B! immunity against SARS-CoV-2 study group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	883-885
Number of pages	3
Journal	Annals of the Rheumatic Diseases
Volume	82
Issue number	6
Early online date	1 Jan 2023
DOIs	https://doi.org/10.1136/ard-2022-223464
Publication status	Published - 1 Jun 2023

Keywords

Covid-19
Vaccination
Autoimmune Diseases
Tumor Necrosis Factor Inhibitors

Access to Document

10.1136/ard-2022-223464

Cite this

Wieske, L., Stalman, E. W., van Dam, P. J. K., Kummer, L. Y., Steenhuis, M., van Kempen, Z. L. E., Killestein, J., Volkers, A. G., Tas, S. W., Boekel, L., Wolbink, G., van der Kooi, A., Raaphorst, J., Lowenberg, M., Takkenberg, B., D'Haens, G. R. A. M., Spuls, P. I., Bekkenk, M. W., Musters, A. H., ... T2B! immunity against SARS-CoV-2 study group (2023). Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 82(6), 883-885. https://doi.org/10.1136/ard-2022-223464

@article{37914ba7448c444b98a01064dafade94,

title = "Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases",

keywords = "Covid-19, Vaccination, Autoimmune Diseases, Tumor Necrosis Factor Inhibitors",

author = "L. Wieske and E.W. Stalman and {van Dam}, P.J.K. and L.Y. Kummer and M. Steenhuis and {van Kempen}, Z.L.E. and J. Killestein and A.G. Volkers and S.W. Tas and L. Boekel and G. Wolbink and {van der Kooi}, A. and J. Raaphorst and M. Lowenberg and B. Takkenberg and G.R.A.M. D'Haens and P.I. Spuls and M.W. Bekkenk and A.H. Musters and N.F. Post and A.L. Bosma and M.L. Hilhorst and Y. Vegting and F.J. Bemelman and A. Voskuyl and B. Broens and A.P. Sanchez and {van Els}, C.A.C.M. and {De Wit}, J. and A. Rutgers and {de Leeuw}, K. and B. Horvath and J.J.G.M. Verschuuren and A.M. Ruiter and {van Ouwerkerk}, L. and {van der Woude}, D. and C.F. Allaart and Y.K.O. Teng and {van Paassen}, P. and M.H. Busch and P.B.P. Jallah and E. Brusse and {van Doorn}, P.A. and A.E. Baars and D. Hijnen and C.R.G. Schreurs and {Van der Pol}, W.L. and H.S. Goedee and S. Keijzer and J. Keijser and {T2B! immunity against SARS-CoV-2 study group}",

note = "Funding Information: FE and TWK report (governmental) grants from ZonMw to studyimmune response after SARS-Cov-2 vaccination in autoimmune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSlBehring; and honoraria from Grifols. AJvdK reports grants from CSLBehring and participation on an advisory board for Argen-X. ML reports agrant from Galapagos not related to this study, and honoraria from BristolMyers Squibb, Pfizer, Takeda and Tillotts. PIS is involved in clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, for example, psoriasis and atopic dermatitis, for which financial compensation is paid to the department or hospital, and is achief investigator of the TREAT NL registry taskforce and SECURE-AD registry. MWB is a secretary for the Dutch Experimental Dermatology Board; head of the pigmentary disorders group within the Dutch Dermatology Board; and reports honoraria from Pfizer, Sanofi, Novartis, and Fondation Ren{\'e} Touraine. JK has speaking relationships with MerckSerono, Biogen Idec, TEVA, Sanofi, Genzyme, Roche and Novartis; received financial support to his institution for researchactivities from Merck Serono, Bayer Shcering Pharma, Biogen Idec, GlaxoSmithKline (GSK), Roche, Teva, Sanofi, Genzyme and Novartis. BH reports unpaid positions as a medical adviser for several patient groups, aboard position for ERN-SKIN, and associate editor for The British Journalof Dermatology; reports grants from AbbVIe, Akari Therapeutics, Celgene and Novartis; consulting fees from UCB Pharma, Novartis, and Janssen; and honoraria from AbbVie. JJGMV reports consulting fees from Argenx, Alexion and NMD Pharma, and is a coinventor on patent applicationsbased on MuSK-related research. DJH reportsgrants from AbbVie, AstraZeneca, Janssen, LEO Pharma and UCB; honoraria from AbbVie, Galderma, Janssen, Lilly, Pfizer, Sanofi, and UCB; and a paid position on an advisory board for BIOMAP IMI. PAvD participated on an advisory board for Octapharma. PvP reports grantsfrom Alexion Pharma and GSK, and participation on advisory boards for GSK and Vifor Pharma. GRAMD{\textquoteright}H reports consulting fees from AbbVie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, BristolMyers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, ExeliomBiosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GSK, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity and Protagonist; honoraria from AbbVie, Arena, Galapagos, Gilead, Pfizer, Bristol MyersSquibb and Takeda; and participation on advisory boards for AbbVie, Seres Health, Galapagos, and AstraZeneca. RBT reports honoraria fromSobi and Norgine, and participation on an advisory board for Norgine. SHG is a board member of the Dutch Society of Clinical Neurophysiology (unpaid), reports grants from Prinses Beatrix Spierfonds, and receivedspeaker fees from Shire/Takeda. KAHZ reports paid data safetymonitoring board positions for Torrent and Foresee. Funding Information: This study was supported by ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007). Funding Information: We thank ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007) for the funding of the study and the T2B partners, including the patient groups, and Health Holland for the support in this study. This collaboration project is financed by the PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF to stimulate public–private partnerships and co-financing by health foundations that are part of the SGF. We also thank E P Moll van Charante (Department of Public and Occupational Health and Department of General Practice, Amsterdam UMC, University of Amsterdam; and Amsterdam Public Health Research Institute, Amsterdam, Netherlands), J A Bogaards (Department of Epidemiology and Data Science), Amsterdam UMC), and R A Scholte (Clinical Research Unit, Amsterdam UMC, University of Amsterdam) for their guidance in the data safety monitoring board. ",

year = "2023",

month = jun,

day = "1",

doi = "10.1136/ard-2022-223464",

language = "English",

volume = "82",

pages = "883--885",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "6",

}

Wieske, L, Stalman, EW, van Dam, PJK, Kummer, LY, Steenhuis, M, van Kempen, ZLE, Killestein, J, Volkers, AG, Tas, SW, Boekel, L, Wolbink, G, van der Kooi, A, Raaphorst, J, Lowenberg, M, Takkenberg, B, D'Haens, GRAM, Spuls, PI, Bekkenk, MW, Musters, AH, Post, NF, Bosma, AL, Hilhorst, ML, Vegting, Y, Bemelman, FJ, Voskuyl, A, Broens, B, Sanchez, AP, van Els, CACM, De Wit, J, Rutgers, A, de Leeuw, K, Horvath, B, Verschuuren, JJGM, Ruiter, AM, van Ouwerkerk, L, van der Woude, D, Allaart, CF, Teng, YKO, van Paassen, P, Busch, MH, Jallah, PBP, Brusse, E, van Doorn, PA, Baars, AE, Hijnen, D, Schreurs, CRG, Van der Pol, WL, Goedee, HS, Keijzer, S, Keijser, J & T2B! immunity against SARS-CoV-2 study group 2023, 'Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases', Annals of the Rheumatic Diseases, vol. 82, no. 6, pp. 883-885. https://doi.org/10.1136/ard-2022-223464

TY - JOUR

T1 - Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

AU - Wieske, L.

AU - Stalman, E.W.

AU - van Dam, P.J.K.

AU - Kummer, L.Y.

AU - Steenhuis, M.

AU - van Kempen, Z.L.E.

AU - Killestein, J.

AU - Volkers, A.G.

AU - Tas, S.W.

AU - Boekel, L.

AU - Wolbink, G.

AU - van der Kooi, A.

AU - Raaphorst, J.

AU - Lowenberg, M.

AU - Takkenberg, B.

AU - D'Haens, G.R.A.M.

AU - Spuls, P.I.

AU - Bekkenk, M.W.

AU - Musters, A.H.

AU - Post, N.F.

AU - Bosma, A.L.

AU - Hilhorst, M.L.

AU - Vegting, Y.

AU - Bemelman, F.J.

AU - Voskuyl, A.

AU - Broens, B.

AU - Sanchez, A.P.

AU - van Els, C.A.C.M.

AU - De Wit, J.

AU - Rutgers, A.

AU - de Leeuw, K.

AU - Horvath, B.

AU - Verschuuren, J.J.G.M.

AU - Ruiter, A.M.

AU - van Ouwerkerk, L.

AU - van der Woude, D.

AU - Allaart, C.F.

AU - Teng, Y.K.O.

AU - van Paassen, P.

AU - Busch, M.H.

AU - Jallah, P.B.P.

AU - Brusse, E.

AU - van Doorn, P.A.

AU - Baars, A.E.

AU - Hijnen, D.

AU - Schreurs, C.R.G.

AU - Van der Pol, W.L.

AU - Goedee, H.S.

AU - Keijzer, S.

AU - Keijser, J.

AU - T2B! immunity against SARS-CoV-2 study group

N1 - Funding Information: FE and TWK report (governmental) grants from ZonMw to studyimmune response after SARS-Cov-2 vaccination in autoimmune diseases. FE also reports grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and GBS-CIDP Foundation; consulting fees from UCB Pharma and CSlBehring; and honoraria from Grifols. AJvdK reports grants from CSLBehring and participation on an advisory board for Argen-X. ML reports agrant from Galapagos not related to this study, and honoraria from BristolMyers Squibb, Pfizer, Takeda and Tillotts. PIS is involved in clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of, for example, psoriasis and atopic dermatitis, for which financial compensation is paid to the department or hospital, and is achief investigator of the TREAT NL registry taskforce and SECURE-AD registry. MWB is a secretary for the Dutch Experimental Dermatology Board; head of the pigmentary disorders group within the Dutch Dermatology Board; and reports honoraria from Pfizer, Sanofi, Novartis, and Fondation René Touraine. JK has speaking relationships with MerckSerono, Biogen Idec, TEVA, Sanofi, Genzyme, Roche and Novartis; received financial support to his institution for researchactivities from Merck Serono, Bayer Shcering Pharma, Biogen Idec, GlaxoSmithKline (GSK), Roche, Teva, Sanofi, Genzyme and Novartis. BH reports unpaid positions as a medical adviser for several patient groups, aboard position for ERN-SKIN, and associate editor for The British Journalof Dermatology; reports grants from AbbVIe, Akari Therapeutics, Celgene and Novartis; consulting fees from UCB Pharma, Novartis, and Janssen; and honoraria from AbbVie. JJGMV reports consulting fees from Argenx, Alexion and NMD Pharma, and is a coinventor on patent applicationsbased on MuSK-related research. DJH reportsgrants from AbbVie, AstraZeneca, Janssen, LEO Pharma and UCB; honoraria from AbbVie, Galderma, Janssen, Lilly, Pfizer, Sanofi, and UCB; and a paid position on an advisory board for BIOMAP IMI. PAvD participated on an advisory board for Octapharma. PvP reports grantsfrom Alexion Pharma and GSK, and participation on advisory boards for GSK and Vifor Pharma. GRAMD’H reports consulting fees from AbbVie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, BristolMyers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, ExeliomBiosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GSK, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity and Protagonist; honoraria from AbbVie, Arena, Galapagos, Gilead, Pfizer, Bristol MyersSquibb and Takeda; and participation on advisory boards for AbbVie, Seres Health, Galapagos, and AstraZeneca. RBT reports honoraria fromSobi and Norgine, and participation on an advisory board for Norgine. SHG is a board member of the Dutch Society of Clinical Neurophysiology (unpaid), reports grants from Prinses Beatrix Spierfonds, and receivedspeaker fees from Shire/Takeda. KAHZ reports paid data safetymonitoring board positions for Torrent and Foresee. Funding Information: This study was supported by ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007). Funding Information: We thank ZonMw (The Netherlands Organisation for Health Research and Development, grant 10430072010007) for the funding of the study and the T2B partners, including the patient groups, and Health Holland for the support in this study. This collaboration project is financed by the PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project number LSHM18055-SGF to stimulate public–private partnerships and co-financing by health foundations that are part of the SGF. We also thank E P Moll van Charante (Department of Public and Occupational Health and Department of General Practice, Amsterdam UMC, University of Amsterdam; and Amsterdam Public Health Research Institute, Amsterdam, Netherlands), J A Bogaards (Department of Epidemiology and Data Science), Amsterdam UMC), and R A Scholte (Clinical Research Unit, Amsterdam UMC, University of Amsterdam) for their guidance in the data safety monitoring board.

PY - 2023/6/1

Y1 - 2023/6/1

KW - Covid-19

KW - Vaccination

KW - Autoimmune Diseases

KW - Tumor Necrosis Factor Inhibitors

U2 - 10.1136/ard-2022-223464

DO - 10.1136/ard-2022-223464

M3 - Article

C2 - 36720583

SN - 0003-4967

VL - 82

SP - 883

EP - 885

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 6

ER -